Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
The researchers compare event rates in users of GLP-1 agonists with those observed in patients selected for other diabetes treatments
A similar pattern was observed in the SURMOUNT-4 trial for tirzepatide: after participants lost an average of 20.9% of their body weight during a 36-week lead-in phase, those who stopped treatment regained about 14%, while those who continued taking tirzepatide lost an additional 5.5% over the next year
Phentermine is FDA-approved for short-term use, typically up to 12 weeks, and GLP-1 medications are designed for long-term, ongoing weight management under provider supervision
Every patient's experience differs and not everyone qualifies for peptide therapy
Eliminate sources of these pollutants by avoiding products that contain BPA, parabens, and phthalates
The Injection May Still Be Better For Patients Seeking Maximum Weight Loss Current evidence still favors injectable semaglutide for peak average weight reduction
